GlassScriptPhysician profile
Ashley Grados
NPI 1720662752
$4,202.68
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $541 · 2022: $2,723 · 2023: $910 · 2024: $29.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $690.76 | 2021-2022 | |
| Abbvie INC. | $679.61 | 2022-2024 | |
| Genzyme Corporation | $529.88 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.46 | 2022-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $256.70 | 2022-2023 | Entyvio, Gattex |
| Amgen INC. | $195.44 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $186.24 | 2022-2024 | Ocaliva |
| Novartis Pharmaceuticals Corporation | $151.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.94 | 2022-2023 | Dupixent |
| Glaxosmithkline, LLC. | $118.15 | 2022 | |
| Janssen Scientific Affairs, LLC | $114.48 | 2022 | |
| Kaleo, INC. | $93.36 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.44 | 2022 | |
| Janssen Biotech, INC. | $77.01 | 2022 | |
| Lundbeck LLC | $75.92 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $64.77 | 2021-2023 | Sucraid |
| Gilead Sciences, INC. | $59.25 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $40.39 | 2021 | |
| Ironwood Pharmaceuticals, INC | $35.12 | 2022 | |
| Upsher-Smith Laboratories LLC | $30.93 | 2021 | |
| Ferring Pharmaceuticals INC. | $27.40 | 2022 | |
| Leo Pharma INC. | $26.68 | 2022 | |
| Csl Behring | $24.85 | 2022 | |
| Nestle Healthcare Nutrition INC. | $24.81 | 2022 | |
| Fresenius Kabi USA, LLC | $19.86 | 2023 | |
| Daiichi Sankyo INC. | $19.83 | 2022 | |
| Alk-Abello, INC | $18.75 | 2022 | |
| Ardelyx, INC. | $17.85 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.46 | 2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.88 | 2022 | |
| Incyte Corporation | $14.69 | 2022 | |
| Pharming Healthcare, INC. | $14.64 | 2021 | |
| Braintree Laboratories, INC. | $13.99 | 2022 | |
| Impel Pharmaceuticals INC. | $13.61 | 2022 | |
| Aimmune Therapeutics, INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Grados listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.